Prasita is an antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Prasita is solely marketed by Ranbaxy in India.
Daiichi Sankyo said that following the April 2009 launch of Olvance (olmesartan medoxomil), an antihypertensive originally discovered by it, Prasita is the second product to be introduced in India through Ranbaxy’s business network.
Ranbaxy will create awareness, understanding and acceptance of the new antiplatelet therapy among the target audiences in the country.
Atul Sobti, managing director and CEO of Ranbaxy, said: “A number of synergy projects between Ranbaxy and Daiichi Sankyo are already underway, and we will further strengthen our common endeavour to realise greater benefits from our Hybrid Business Model.”
Takashi Shoda, president and CEO of Daiichi Sankyo, said: “The launch of our two products, Olmesartan medoxomil and Prasugrel, by Ranbaxy shows our serious commitment to India, and we will continue to explore further collaborations leveraging the Hybrid Business Model.”